CTIS2023-504957-11-00招募中1 期
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA) - MK-5684-004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •1.Have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology, 6.Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<1.7 nM), 7.Has an eastern clinical oncology group (ECOG) performance status of 0 or 1 assessed within 7 days before randomization, 8.Has adequate organ function, 9.Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated. Samples from tumors progressing at a prior site of radiation are allowed, 10.Participants who are hepatitis B surface antigen (HbsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization, 11.Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening, 12.Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to =Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy (HRT) or participants who have =Grade 2 neuropathy are eligible, 13.Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART), 2.Has prostate cancer progression while receiving androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening, 3.Has current evidence of metastatic disease documented by either bone lesions on bone scan and/or soft tissue disease shown by computed tomography scan (CT)/magnetic resonance imaging (MRI), 4.Has disease that progressed during or after treatment with one next-generation hormonal agent (NHA) for hormone sensitive prostate cancer (HSPC) metastatic hormone sensitive prostate cancer (mHSPC) or non metastatic hormone sensitive prostate cancer (nmHSPC), for at least 8 weeks (at least 14 weeks for participants with bone progression) Note: Participants may have received abiraterone acetate and docetaxel or darolutamide and docetaxel for HSPC. However, participants must have received no more than six cycles of docetaxel and had no radiographic disease progression while receiving docetaxel, 5.Has had prior treatment with Poly polymerase inhibitors (PARPi) or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
排除标准
- •1.Has presence of gastrointestinal condition, 10.Has received a taxane-based chemotherapy and or NHA for metastatic castration-resistant prostate cancer (mCRPC), 11.Has not adequately recovered from major surgery or have ongoing surgical complications, 12.Has received prior treatment with radium for prostate cancer, 13.Is currently being treated with Cytochrome P450 (CYP450)-inducing antiepileptic drugs for seizures, 14.Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention, 15.Receives prior radiotherapy within 2 weeks before the first dose of study intervention, or radiation-related toxicities, requiring corticosteroids, 16.Receives prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention, 17.Has systemic use of strong Cytochrome P450 3A4 (CYP3A4) inducers and P-glycoprotein (P-gp) inhibitors within 2 weeks before the first dose of study intervention, 18.Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention, 19.Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention, 2.Is unable to swallow capsules/tablets, 20.Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration, 21.Has known hypersensitivity to the components or excipients in abiraterone acetate, prednisone or prednisolone, or enzalutamide, 22.Has a superscan” bone scan defined as an intense symmetric activity in the bones and diminished renal parenchymal activity on baseline bone scan such that the presence of additional metastases in the future could not be evaluated, 23.Has known additional malignancy that is progressing or has required active treatment within the past 3 years, 24.Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication, 25.Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during study screening, are clinically stable and have not required steroid treatment for at least 14 days prior to the first dose of study intervention, 26.Has active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is allowed. 27. Active infection requiring systemic therapy. 28. Has concurrent active Hepatitis B virus and Hepatitis C virus infection., 3.Has history of pituitary dysfunction, 4.Has poorly controlled diabetes mellitus, 5.Has clinically significant abnormal serum potassium or sodium level. Has any of the following at Screening Visit: Hypotension: systolic BP <110 mmHg, or Uncontrolled hypertension: systolic BP >160mmHg or diastolic BP >90 mmHg, in 2 out of the 3 recordings with optimized antihypertensive therapy, 6.Has history or family history of long QTc syndrome, 7.Has a history of seizure(s) within 6 months prior to signing the IC or has any condition that may predispose to seizure within 12 months prior to the date of enrollment, 8.Has active or unstab
研究者
相似试验
尚未招募
3 期
Phase 3 study of MK-5684 versus alternative NHA in mCRPC Acronym: MK-5684-003D075 ProstateProstateD075PER-048-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)
招募中
1 期
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and chemotherapyMetastatic castration resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-504899-25-00Merck Sharp & Dohme LLC1,246
尚未招募
3 期
Phase 3 Study of MK-5684 Versus Alternative Treatment with an NHA in mCRPC After Treatment with an NHAD075 ProstateProstateD075PER-047-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)
进行中（未招募）
1 期
An Open-label, Randomized Phase 3 Study of MK-6482 versus Everolimus in Participants with Advanced Renal Cell Carcinoma that has Progressed After Prior TherapyAdvanced Renal Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003444-72-ESMerck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc736
进行中（未招募）
1 期
An Open-label, Randomized Phase 3 Study of MK-6482 versus Everolimus in Participants with Advanced Renal Cell Carcinoma that has Progressed After Prior TherapyAdvanced Renal Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003444-72-DKMerck Sharp & Dohme LLC736